[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Liu et al., 2016 - Google Patents

Discovery of pyrazolo [1, 5-a] pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agent

Liu et al., 2016

View HTML
Document ID
16231770293736946218
Author
Liu Y
Laufer R
Patel N
Ng G
Sampson P
Li S
Lang Y
Feher M
Brokx R
Beletskaya I
Hodgson R
Plotnikova O
Awrey D
Qiu W
Chirgadze N
Mason J
Wei X
Lin D
Che Y
Kiarash R
Fletcher G
Mak T
Bray M
Pauls H
Publication year
Publication venue
ACS Medicinal Chemistry Letters

External Links

Snippet

This work describes a scaffold hopping exercise that begins with known imidazo [1, 2-a] pyrazines, briefly explores pyrazolo [1, 5-a][1, 3, 5] triazines, and ultimately yields pyrazolo [1, 5-a] pyrimidines as a novel class of potent TTK inhibitors. An X-ray structure of a …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulfur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Similar Documents

Publication Publication Date Title
Liu et al. Discovery of pyrazolo [1, 5-a] pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agent
Kusakabe et al. Discovery of imidazo [1, 2-b] pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity
Mao et al. Overview of research into mTOR inhibitors
Goldberg et al. The Discovery of 7-Methyl-2-[(7-methyl [1, 2, 4] triazolo [1, 5-a] pyridin-6-yl) amino]-9-(tetrahydro-2 H-pyran-4-yl)-7, 9-dihydro-8 H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
Pike et al. The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino) propoxy] pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1, 3-dihydro-2 H-imidazo [4, 5-c] quinolin-2-one)
Jorda et al. Pyrazolo [4, 3-d] pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity
Degorce et al. Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase
Ward et al. Structure-guided design of highly selective and potent covalent inhibitors of ERK1/2
Paruch et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases
Zask et al. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines
Toogood et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Saurat et al. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors
Huang et al. Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer
Tao et al. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors
Xu et al. Synthesis and biological evaluation of pyrazolo [1, 5-a] pyrimidine compounds as potent and selective Pim-1 inhibitors
Gucky et al. A novel series of highly potent 2, 6, 9-trisubstituted purine cyclin-dependent kinase inhibitors
Jain et al. Discovery of potent and selective RSK inhibitors as biological probes
Schulze et al. Treating cancer by spindle assembly checkpoint abrogation: discovery of two clinical candidates, BAY 1161909 and BAY 1217389, targeting MPS1 kinase
Patel et al. 2, 4, 6-Triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors
Woodward et al. Introduction of a Methyl Group Curbs Metabolism of Pyrido [3, 4-d] pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N 2-(2-Ethoxy-4-(4-methyl-4 H-1, 2, 4-triazol-3-yl) phenyl)-6-methyl-N 8-neopentylpyrido [3, 4-d] pyrimidine-2, 8-diamine (BOS172722)
Pei et al. Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
Ren et al. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2
Innocenti et al. Rapid discovery of pyrido [3, 4-d] pyrimidine inhibitors of monopolar spindle kinase 1 (MPS1) using a structure-based hybridization approach
Gangjee et al. 2-Amino-4-oxo-5-substituted-pyrrolo [2, 3-d] pyrimidines as Nonclassical Antifolate Inhibitors of Thymidylate Synthase1a, b
Liu et al. Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase